HONG KONG, September 6, 2017 (Newswire.com) - Lotus Bio-Technology Development Corp. (OTC PINK: LBTD), ("the Company") is pleased to announce it will be undertaking previously announced investments into CBD and Medical Cannabis product development.
In November of 2016 the Company issued a press release detailing its intentions of developing a CBD product line. The subsequent resignation of the Company's former CEO in February of 2017 initially stalled those initiatives. With much of the previous pipeline still in place, as well as stronger partnerships secured, the company is ready to move forward aggressively to develop world class CBD based products for the growing Medical Marijuana sector.
The Company’s strategic Chinese partnerships, such as Hunan Cangshi, a successful proprietor, developer, and producer of consumer related organic products, Phyto Nutraceutical Inc., a developer, manufacturer, exporter, and primary supplier of plant extracts and Changsha Huakang Biotechnology Development Co., Ltd, which specializes in extracting active ingredients of natural herbs and plants, places Lotus Bio-Tech in unique position to procure and develop high quality products and compete for significant market share in the Cannabis Industry.
The company will also be seeking U.S.-based strategic partnerships to help facilitate with its end user supply chain for new products as well as to explore additional opportunities within the Medical Marijuana space.
About Lotus Bio-Technology Corp: Lotus Bio-Technology is actively seeking new opportunities in the emerging bio-natural industry in China. Our mandate is to partner with companies that are in the organic growth sector that meet the criteria we have set out to grow various plants under strict organic standards. Plants that can be refined into various products which are completely natural and strike a balance between affordability while being produced from an environmentally responsible manner. Products that are void of pesticides, synthetic fertilizers, antibiotics, growth hormones and any other dangerous chemicals. The Company has offices in China and Cave Creek, Arizona USA.
Cautionary Note Regarding Forward-Looking Statements: This news release contains forward-looking statements about our business or financial condition and prospects that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this news release, words such as "believes," "expects," "intends," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain forward-looking statements not accompanied by such expressions. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including risks discussed in the company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (www.sec.gov). All forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by these factors other than as required under the securities laws. The Company does not assume a duty to update these forward-looking statements.
Source: Lotus Bio-Technology Development Corp.